These findings demonstrate that fludarabine‐mediated STAT1 inhibition ameliorates vitiligo progression by suppressing macrophage‐driven inflammation, reducing T cell activity, preserving MELs, and promoting melanogenesis. The gene discussed is STAT1; the disease is vitiligo.